{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:07:56Z","timestamp":1779235676107,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T00:00:00Z","timestamp":1503878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T00:00:00Z","timestamp":1503878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40744-017-0076-0","type":"journal-article","created":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T08:26:04Z","timestamp":1503908764000},"page":"233-246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Review of the Use of Secukinumab for Psoriatic Arthritis"],"prefix":"10.1007","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-6357","authenticated-orcid":false,"given":"Nupur U.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora C.","family":"Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily Rose","family":"Shealy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,28]]},"reference":[{"key":"76_CR1","unstructured":"National Psoriasis Foundation. Fact Sheet Library | National Psoriasis Foundation. https:\/\/www.psoriasis.org\/publications\/patient-education\/fact-sheets. Accessed 30 May 2017."},{"issue":"5","key":"76_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section\u00a02. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851\u201364. doi:10.1016\/j.jaad.2008.02.040.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"76_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jaad.2014.05.010","volume":"71","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Gladman DD, Helliwell P, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2014;71(4):649\u201355. doi:10.1016\/j.jaad.2014.05.010.","journal-title":"J Am Acad Dermatol"},{"key":"76_CR4","unstructured":"Cosentyx (secukinumab) [prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation. 2016."},{"issue":"1","key":"76_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40744-016-0031-5","volume":"3","author":"P Mease","year":"2016","unstructured":"Mease P, McInnes IB. Secukinumab: a new treatment option for psoriatic arthritis. Rheumatol Ther. 2016;3(1):5\u201329. doi:10.1007\/s40744-016-0031-5.","journal-title":"Rheumatol Ther."},{"issue":"6","key":"76_CR6","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020\u20136. doi:10.1136\/annrheumdis-2013-205056.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"76_CR7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"P Miossec","year":"2009","unstructured":"Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888\u201398. doi:10.1056\/NEJMra0707449.","journal-title":"N Engl J Med"},{"issue":"10","key":"76_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrd3794","volume":"11","author":"P Miossec","year":"2012","unstructured":"Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763\u201376. doi:10.1038\/nrd3794.","journal-title":"Nat Rev Drug Discov."},{"issue":"2","key":"76_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/art.38291","volume":"66","author":"JA Smith","year":"2014","unstructured":"Smith JA, Colbert RA. Review: the interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: th17 and beyond. Arthritis Rheumatol. 2014;66(2):231\u201341. doi:10.1002\/art.38291.","journal-title":"Arthritis Rheumatol."},{"issue":"1\u20132","key":"76_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","volume":"359","author":"SP Raychaudhuri","year":"2012","unstructured":"Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1\u20132):419\u201329. doi:10.1007\/s11010-011-1036-6.","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"76_CR11","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/art.38376","volume":"66","author":"B Menon","year":"2014","unstructured":"Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+ CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272\u201381. doi:10.1002\/art.38376.","journal-title":"Arthritis Rheumatol."},{"key":"76_CR12","doi-asserted-by":"crossref","unstructured":"Lubberts E, Joosten LA, Oppers B, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol. 2001;167(2):1004\u20131013. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11441109. Accessed 6 Apr 2017.","DOI":"10.4049\/jimmunol.167.2.1004"},{"key":"76_CR13","unstructured":"Novartis. Cosentyx summary of product characteristics. http:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150115130444\/anx_130444_en.pdf. Accessed 30 July 2017."},{"issue":"14","key":"76_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339. doi:10.1056\/NEJMoa1412679.","journal-title":"N Engl J Med"},{"issue":"2","key":"76_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73(2):349\u201356. doi:10.1136\/annrheumdis-2012-202646.","journal-title":"Ann Rheum Dis"},{"issue":"9999","key":"76_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346. doi:10.1016\/S0140-6736(15)61134-5.","journal-title":"Lancet"},{"key":"76_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2015-eular.2276","volume":"74","author":"B Kirkham","year":"2015","unstructured":"Kirkham B, McInnes I, Mease P, et al. THU0421 secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (future 2). Ann Rheum Dis. 2015;74:351. doi:10.1136\/annrheumdis-2015-eular.2276.","journal-title":"Ann Rheum Dis."},{"key":"76_CR18","unstructured":"Novartis. Expert insights on the approved uses of COSENTYX (secukinumab). In: American College of Rheumatology annual 2016 meeting. Washington, DC. 2016."},{"key":"76_CR19","unstructured":"Data on file. AIN457F summary of clinical safety in psoriatic arthritis. Novartis Pharmaceuticals Corp. 2015."},{"issue":"2\u20133","key":"76_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12026-011-8226-x","volume":"50","author":"SL Gaffen","year":"2011","unstructured":"Gaffen SL, Hern\u00e1ndez-Santos N, Peterson AC. IL-17 signaling in host defense against Candida albicans. Immunol Res. 2011;50(2\u20133):181\u20137. doi:10.1007\/s12026-011-8226-x.","journal-title":"Immunol Res"},{"issue":"12","key":"76_CR21","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700. doi:10.1136\/gutjnl-2011-301668.","journal-title":"Gut"},{"key":"76_CR22","unstructured":"Data on file. AIN457H summary of clinical efficacy in ankylosing spondylitis. Novartis Pharmaceuticals Corp. 2015."},{"issue":"1","key":"76_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","volume":"75","author":"PCM van de Kerkhof","year":"2016","unstructured":"van de Kerkhof PCM, Griffiths CEM, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83\u201398.e4. doi:10.1016\/j.jaad.2016.03.024.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"76_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijwd.2016.12.003","volume":"3","author":"ML Porter","year":"2017","unstructured":"Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017;3(1):21\u20135. doi:10.1016\/j.ijwd.2016.12.003.","journal-title":"Int J Womens Dermatol."},{"key":"76_CR25","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.2147\/DDDT.S105263","volume":"10","author":"MI Koenders","year":"2016","unstructured":"Koenders MI, van den Berg WB. Secukinumab for rheumatology: development and its potential place in therapy. Drug Des Dev Ther. 2016;10:2069\u201380. doi:10.2147\/DDDT.S105263.","journal-title":"Drug Des Dev Ther."},{"key":"76_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;. doi:10.1002\/art.39573.","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"76_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510. doi:10.1136\/annrheumdis-2015-208337.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"76_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrrheum.2016.183","volume":"12","author":"L Gossec","year":"2016","unstructured":"Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12(12):743\u201350. doi:10.1038\/nrrheum.2016.183.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"76_CR29","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/bjd.14667","volume":"174","author":"LC Coates","year":"2016","unstructured":"Coates LC, Murphy R, Helliwell PS. New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol. 2016;174(6):1174\u20138. doi:10.1111\/bjd.14667.","journal-title":"Br J Dermatol"},{"key":"76_CR30","doi-asserted-by":"publisher","unstructured":"Oussedik E, Cardwell LA, Patel NU, Onikoyi O, Feldman SR. An anchoring-based intervention to increase patient willingness to use injectable medication in psoriasis.\u00a0JAMA Dermatol.\u00a02017. doi:10.1001\/jamadermatol.2017.1271.","DOI":"10.1001\/jamadermatol.2017.1271"},{"issue":"26","key":"76_CR31","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348. doi:10.1056\/NEJMoa1505066.","journal-title":"N Engl J Med."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-017-0076-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-017-0076-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-017-0076-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:09:30Z","timestamp":1724458170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-017-0076-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,28]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1007\/s40744-017-0076-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,28]]},"assertion":[{"value":"7 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}